Regeneron Pharmaceuticals, Inc. $REGN Shares Newly Purchased by Quadcap Wealth Management LLC

Quadcap Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, Holdings Channel reports. The fund acquired 631 shares of the biopharmaceutical company’s stock, valued at approximately $478,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. BlackRock Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $5,682,636,000. Legal & General Group Plc bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $473,872,000. Bank of New York Mellon Corp bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $472,950,000. Deutsche Bank AG bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $323,249,000. Finally, Man Group plc purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $272,460,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Joseph Larosa sold 4,466 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total value of $4,311,878.34. Following the sale, the executive vice president directly owned 38,906 shares in the company, valued at $37,563,353.94. The trade was a 10.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Christine Poon sold 7,830 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $969.09, for a total value of $7,587,974.70. Following the transaction, the director directly owned 5,219 shares in the company, valued at $5,057,680.71. This represents a 60.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 28,228 shares of company stock valued at $25,985,950. Company insiders own 6.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Morgan Stanley upped their price objective on Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the company an “equal weight” rating in a research note on Monday, November 2nd. HSBC upped their price objective on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Robert W. Baird raised their target price on Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the company a “neutral” rating in a research report on Monday, November 2nd. Finally, Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $898.97.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded up $1.45 on Friday, reaching $904.35. 1,122,229 shares of the company traded hands, compared to its average volume of 793,479. The company has a 50 day moving average of $804.38 and a 200 day moving average of $742.81. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66. Regeneron Pharmaceuticals, Inc. has a 52 week low of $591.52 and a 52 week high of $991.73. The firm has a market capitalization of $93.11 billion, a PE ratio of 19.97, a PEG ratio of 1.51 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. During the same quarter in the previous year, the firm posted $11.83 EPS. Regeneron Pharmaceuticals’s revenue was up 36.3% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.